Disciform Scar: End-Stage Macular Degeneration
Understanding Disciform Scars
A disciform scar is a round or disc-shaped area of dense scar tissue that replaces the normal structures of the macula. The scar forms after abnormal blood vessels beneath the retina repeatedly leak blood and fluid over time. The body attempts to heal this damage by producing fibrous tissue, much like a scar forms on the skin after a wound. This scar tissue destroys the light-sensing photoreceptor cells and the retinal pigment epithelium (RPE), a layer of cells that supports the retina.
The result is a lasting blind spot in the center of vision. Peripheral or side vision typically remains intact because the scarring is confined to the macula. Before modern treatments became available, disciform scars were a common end result of wet AMD. Today, large scars are less frequent thanks to anti-VEGF therapy (medications that block abnormal blood vessel growth), but smaller areas of fibrosis still develop in many patients over time.
The process begins with choroidal neovascularization (CNV). Abnormal blood vessels grow from beneath the retina through a thin layer called Bruch's membrane. These fragile new vessels leak blood plasma and fluid into the space beneath or within the retina. The leaked material creates a framework that attracts fibroblasts, cells that produce scar tissue.
A process called epithelial-mesenchymal transition also plays a role. During this process, retinal pigment epithelial cells change their identity and begin acting like scar-producing cells. They deposit collagen and other fibrous proteins. Over time, the blood vessels within the scar mature and draw blood flow away from surrounding tissue. This causes the RPE around the scar to atrophy. The damaged area can expand to more than three times the size of the original lesion.
Disciform scars are the end stage of neovascular or wet AMD. Not all patients with AMD develop this type of scarring. Approximately 10% to 20% of patients with dry AMD eventually progress to the wet form (NEI, 2023). It is this wet form that can lead to disciform scarring if the abnormal vessels are not controlled.
Who Is Affected and Risk Factors
Age is the strongest risk factor for disciform scar formation. The prevalence of AMD increases significantly after age 60. The risk of progression to the wet form rises with each decade. People of Caucasian descent have a higher risk of developing AMD compared to other racial groups.
Genetic factors play a meaningful role in who develops wet AMD and subsequent scarring. Variants in genes such as complement factor H (CFH) and ARMS2 are associated with a higher risk of AMD progression. Having a family member with AMD increases a person's own risk. If one eye has developed a large disciform scar, 50% of fellow eyes develop similarly sized lesions over time (Macular Photocoagulation Study Group, 1991). In contrast, only 16% of fellow eyes with small scars in one eye go on to develop large scars (Macular Photocoagulation Study Group, 1991).
Smoking is one of the most significant modifiable risk factors. Current or past smoking nearly doubles the risk of developing AMD and its complications, including disciform scarring. Cardiovascular disease, high blood pressure, and obesity are also associated with a higher likelihood of progression.
Dietary factors matter as well. A diet high in saturated fat and low in antioxidants such as vitamins C, E, zinc, and lutein may contribute to AMD risk. Prolonged exposure to ultraviolet light without eye protection is another environmental factor.
One of the most important risk factors for disciform scar formation is delayed or insufficient treatment of active wet AMD. When CNV is not promptly treated with anti-VEGF injections, the abnormal vessels continue to leak and bleed. Over weeks to months, this ongoing damage triggers the fibrotic healing response that leads to scarring. Patients who miss appointments or discontinue treatment prematurely face a higher risk.
Signs and Symptoms
The hallmark symptom of a disciform scar is a dense, fixed blind spot in the center of vision called a scotoma. Unlike the fluctuating vision changes that occur during active wet AMD, the vision loss from a disciform scar does not come and go. Patients often describe a dark or gray area directly in the center of what they are looking at. This blind spot cannot be corrected with glasses or contact lenses.
Before the scar fully matures, patients may notice significant distortion of their vision, known as metamorphopsia. Straight lines may appear wavy, bent, or broken. Faces may look uneven or distorted. These distortion symptoms can occur during active CNV and may persist even after scarring is complete.
Patients with disciform scars commonly struggle with tasks that require central vision. Reading becomes difficult or impossible without magnification aids. Recognizing faces, watching television, driving, and performing detailed work may be significantly impaired. Peripheral vision typically remains functional, so patients can usually navigate their surroundings.
Any sudden change in vision in a patient with known AMD requires urgent evaluation. A rapid increase in distortion, a new blind spot, or sudden worsening of vision may indicate reactivation of abnormal blood vessels at the edge of an existing scar. Even eyes with established disciform scars can experience new CNV activity. Prompt treatment of reactivation may help preserve the remaining vision around the scar.
Diagnosis and Testing
A retina specialist diagnoses a disciform scar through a dilated eye examination. During this exam, the specialist uses special lenses to view the retina in detail. A disciform scar appears as a whitish or grayish, elevated area in the macula. The scar may be surrounded by areas of RPE atrophy or pigment changes.
Optical coherence tomography (OCT) is one of the most important tools for evaluating disciform scars. OCT uses light waves to create detailed cross-sectional images of the retina. On OCT, a disciform scar appears as a dense, highly reflective mass replacing the normal retinal layers. The scan also reveals the extent of photoreceptor loss, RPE destruction, and any residual fluid that might suggest ongoing CNV activity.
Fluorescein angiography involves injecting a yellow dye into a vein in the arm and photographing the dye as it flows through retinal blood vessels. This test helps a retina specialist determine whether any active leakage is present at the edges of the scar. In a mature disciform scar, the central area typically shows staining without active leakage. Any new leakage at the periphery may indicate CNV reactivation.
Indocyanine green (ICG) angiography uses a different dye to visualize the deeper choroidal blood vessels beneath the retina. This test is particularly useful for identifying feeder vessels that supply a disciform scar. ICG angiography can also detect subtle areas of CNV reactivation and guide targeted treatment in select cases.
Treatment Options
The most effective approach to disciform scars is preventing them from forming. Anti-VEGF therapy is the standard treatment for active wet AMD. These medications block vascular endothelial growth factor (VEGF), a protein that promotes abnormal blood vessel growth and leakage.
Available anti-VEGF medications include:
- Eylea (aflibercept), typically given every 4 to 8 weeks after initial loading doses
- Eylea HD (high-dose aflibercept), which may allow longer intervals of 8 to 16 weeks
- Lucentis (ranibizumab), given approximately every 4 weeks
- Avastin (bevacizumab), which is FDA-approved for cancer and used off-label for eye conditions, given every 4 to 6 weeks
- Vabysmo (faricimab), a bispecific antibody given every 4 to 16 weeks
- Beovu (brolucizumab), given every 8 to 12 weeks
Data from the CATT clinical trial show that anti-VEGF therapy dramatically reduces the formation of large disciform scars compared to the era before these treatments existed (CATT Research Group, 2012). However, findings from the HARBOR study indicate that fibrosis still develops in many patients despite intensive treatment (HARBOR Study Group, 2014). This suggests that biological pathways beyond VEGF contribute to scar formation. Research into combination therapies that target multiple fibrotic pathways is ongoing. It is important to note that anti-VEGF injections are used specifically for wet AMD and are not a treatment for dry AMD.
Once a disciform scar has fully formed, the central vision loss it causes does not improve with current treatments. There is no therapy that can remove the scar or regenerate the destroyed photoreceptors and RPE. Treatment at this stage focuses on monitoring for CNV reactivation at the edges of the scar and helping the patient maximize remaining vision.
In some cases, reactivation of abnormal blood vessels occurs at the scar periphery. When this happens, a retina specialist may resume anti-VEGF injections or use focal laser photocoagulation to seal active vessels and protect surrounding retina from further damage.
Low vision rehabilitation is a critical part of care for patients with disciform scars. A low vision specialist can prescribe magnifying devices, specialized reading glasses, electronic magnifiers, and other adaptive tools. Training in eccentric viewing techniques teaches the patient to use areas of the retina outside the scar for reading and other tasks. Many patients find they can continue reading, using a computer, and performing household tasks with appropriate support.
What to Expect
Patients with a disciform scar typically have a dense central blind spot that does not improve over time. The size of the blind spot depends on the size of the scar. Peripheral vision remains intact in most cases. The brain often adapts over time, and many patients learn to use their side vision more effectively.
If a disciform scar has formed in one eye, close monitoring of the other eye is essential. Research shows a significant risk of developing wet AMD in the fellow eye. Regular examinations by a retina specialist, typically every few months, help detect early signs of CNV. Home monitoring with an Amsler grid, a simple chart with a grid pattern, can help patients detect distortion between appointments.
While the central vision affected by the scar will not recover, most patients retain enough peripheral vision to remain independent. The area of atrophy around the scar may slowly expand over years. Ongoing follow-up appointments allow a retina specialist to detect any changes early. With proper low vision support and regular monitoring, many patients maintain a good quality of life.
Living with a Disciform Scar
Living with central vision loss requires practical adjustments. Increasing lighting in the home, using large-print materials, and positioning items in consistent locations can help. Many patients benefit from audiobooks, voice-activated devices, and smartphone accessibility features.
Losing central vision can be emotionally challenging. Feelings of frustration, sadness, or anxiety are common and understandable. Support groups for people with vision loss, counseling, and community resources can provide valuable help. Staying socially active and engaged in hobbies supports both emotional well-being and cognitive health.
Patients who have a disciform scar in one eye should take steps to protect the vision in their other eye. This includes attending all scheduled appointments with a retina specialist and using the Amsler grid daily to check for new distortion. Wearing sunglasses with UV protection outdoors, not smoking, and maintaining a healthy diet rich in leafy green vegetables and fish are also important. AREDS2 vitamin supplements, as recommended by a retina specialist, may help reduce the risk of progression in the fellow eye (NEI, 2013).
When to See a Retina Specialist
See a retina specialist or go to the emergency room immediately if you experience any of the following symptoms:
- A sudden increase in the size of a central blind spot
- New or worsening distortion where straight lines appear wavy or bent
- A sudden, noticeable drop in vision in either eye
- A dark shadow or curtain-like effect across part of your vision
- New flashes of light or a sudden increase in floaters
Even when a disciform scar appears stable, regular follow-up with a retina specialist is important. These visits allow for OCT imaging to detect subtle changes, evaluation of the fellow eye, and adjustments to any ongoing treatment. The frequency of visits depends on the specific situation but is often every three to six months for a stable scar.
Questions and Answers
A disciform scar cannot be reversed or surgically removed with current medical technology. The scar replaces the photoreceptor cells and retinal pigment epithelium, which are structures that do not regenerate on their own. Research into therapies such as RPE cell transplantation and gene therapy is ongoing, but no proven treatment currently exists to restore vision lost to a disciform scar. The focus of care is on preserving remaining vision and maximizing quality of life through low vision rehabilitation.
Having a disciform scar in one eye does increase the risk of developing wet AMD in the fellow eye, but it does not mean vision loss in the other eye is certain. Research shows that 50% of fellow eyes with large macular scars develop similarly sized lesions over time (Macular Photocoagulation Study Group, 1991). Regular monitoring by a retina specialist and daily use of an Amsler grid at home can help detect early changes. If wet AMD is caught early and treated promptly, the risk of developing a disciform scar in the second eye is significantly lower than it was before anti-VEGF therapy became available.
A disciform scar and geographic atrophy (GA) are both advanced forms of AMD, but they arise from different processes. A disciform scar results from wet AMD, where abnormal blood vessels leak and bleed, and the body responds by forming fibrous scar tissue. Geographic atrophy is a form of advanced dry AMD, where the RPE and photoreceptors gradually waste away without abnormal blood vessel growth. Both conditions cause lasting central vision loss, but their causes and treatments are distinct. Anti-VEGF therapy targets wet AMD and scar prevention. Geographic atrophy has its own class of treatments: complement inhibitors such as Syfovre (pegcetacoplan), a C3 inhibitor, and Izervay (avacincaptad pegol), a C5 inhibitor, are FDA-approved specifically for slowing GA progression.
Researchers are actively studying new approaches to address fibrosis in wet AMD. Current anti-VEGF medications may have some antifibrotic properties beyond their effects on blood vessel growth (CATT Research Group, 2012). Combination therapies that target multiple pathways involved in scar formation are being explored in clinical trials. Cell-based therapies, including RPE transplantation, and gene therapy approaches are also in early stages of research. While these developments offer hope for the future, none have yet been proven safe and effective enough for routine clinical use.
Driving ability depends on the extent of vision loss and the legal requirements in your state or region. If the disciform scar is in only one eye and the other eye has good vision, many patients can continue to drive. If both eyes are affected or if the central blind spot impairs the ability to see road signs and pedestrians, driving may no longer be safe. A retina specialist or low vision specialist can assess your visual function and advise you. Some patients benefit from a formal driving evaluation by a certified driving rehabilitation specialist.